Clinical Diagnosis and Treatment Recommendations for the Pneumonitis Associated with Immune Checkpoint Inhibitor / 中国肺癌杂志
Chinese Journal of Lung Cancer
;
(12): 621-626, 2019.
Artículo
en Chino
| WPRIM
| ID: wpr-775582
ABSTRACT
The increasing use of immunocheckpoint inhibitors in tumors has brought new hope of survival to patients with advanced tumors. However, the immune system activated by immunocheckpoint inhibitors, mainly activated T-cell immunity, may attack normal tissues and organs of the human body and lead to a variety of adverse effects. In the lung, they could induce checkpoint inhibitor associated pneumonitis (CIP). CIP is different from known pulmonary interstitial pneumonitis, and had a potentially fatal risk if it was not being properly treated. We will summarize the characteristics of CIP and give our advice on how to manage immunocheckpoint inhibitor associated pneumonitis.
Texto completo:
Disponible
Índice:
WPRIM (Pacífico Occidental)
Tipo de estudio:
Estudio diagnóstico
/
Guía de Práctica Clínica
Idioma:
Chino
Revista:
Chinese Journal of Lung Cancer
Año:
2019
Tipo del documento:
Artículo
Similares
MEDLINE
...
LILACS
LIS